PAR 5.77% 24.5¢ paradigm biopharmaceuticals limited..

National MPS Society 35th Conference, page-15

  1. 281 Posts.
    lightbulb Created with Sketch. 107
    Another good post Mozz, and many thanks for your work.

    To your knowledge, are there any other off-patent drugs (or on-patent for that matter), where the manufacturers, or license holders, are charging the patients or the insurance companies a price which varies according to the illness for which it's being prescribed? i.e do you think it's commercially viable for PAR to charge say $2k for a course of iPPS when it's being used to treat OA, but $50k (!) if it's being prescribed for MPS?

    I have no doubts whatsoever as to iPPS's efficacy in the treatment of OA, but in terms of monetizing the product I remain cautiously pessimistic.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.5¢
Change
-0.015(5.77%)
Mkt cap ! $85.70M
Open High Low Value Volume
26.0¢ 26.0¢ 24.5¢ $265.4K 1.050M

Buyers (Bids)

No. Vol. Price($)
8 130186 24.5¢
 

Sellers (Offers)

Price($) Vol. No.
25.0¢ 11571 1
View Market Depth
Last trade - 16.10pm 31/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.